Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Genmab Announces Tepkinly® In Combination With Lenalidomide And Rituximab Is Approved By The European Commission

    Picture of Genmab A/S logoGenmab A/S
    06/07/2026 18:48
    BRIEF-Genmab Announces Tepkinly® In Combination With Lenalidomide And Rituximab Is Approved By The European Commission 
    July 6 (Reuters) - Genmab A/S GMAB.CO:
    • GENMAB ANNOUNCES TEPKINLY® (EPCORITAMAB) IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IS APPROVED BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    • GENMAB - PHASE 3 EPCORE FL-1: TEPKINLY PLUS R(2) SHOWS SUPERIOR EFFICACY WITH 75% COMPLETE RESPONSE RATE
    • GENMAB - TEPKINLY PLUS R(2) REDUCES RISK OF DISEASE PROGRESSION OR DEATH BY 79% VERSUS R(2) ALONE
    Source text: ID:nBw54W7f3a
    Further company coverage: GMAB.CO

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news